Literature DB >> 17656010

CD133-enriched CD34(-) (CD33/CD38/CD71)(-) cord blood cells acquire CD34 prior to cell division and hematopoietic activity is exclusively associated with CD34 expression.

Katharina S Götze1, Matthias Schiemann, Stefanie Marz, Volker R Jacobs, Gerlinde Debus, Christian Peschel, Robert A J Oostendorp.   

Abstract

We compared the cell division behavior of CD34(-) and CD34(+) (CD33/CD38/CD71)-negative (Lin(-)) CD133(+) cord blood cells stimulated with the cytokines Flt3-ligand, stem cell factor, and thrombopoietin. Within a 4-day time frame, Lin(-)CD34(-) CD133(+) (CD34(-)) cells underwent more cell divisions in serum-free culture than their Lin(-)CD34(+) CD133(+) (CD34(+)) counterparts. The majority of CD34(-) cells acquired expression of CD34 in vitro, including most undivided cells. Moreover, hematopoietic activity from both CD34(-) and CD34(+) cells was exclusively retained within the cell fraction expressing CD34 after 4 days in culture. Most strikingly, in cultures from Lin(-)CD34(-) cells hematopoietic activity was associated with the fraction of divided cells, whereas in cultures of CD34(+) cells, hematopoietic activity associated with the undivided cell fraction. Therefore, clonogenic CD34(+) cells either do not divide or lose their clonogenic capacity upon cell division in vitro, while CD34(-) cells divide and retain this capacity under the same specific conditions. In conclusion, we demonstrate that CD133-enriched Lin(-)CD34(-) cord blood cells acquire CD34 prior to cell division and that long-term hematopoietic activity is associated exclusively with expression of CD34.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656010     DOI: 10.1016/j.exphem.2007.05.016

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  7 in total

1.  Immunophenotyping of hematopoietic progenitor cells: Comparison between cord blood and adult mobilized blood grafts.

Authors:  Nesrine Ben Azouna; Lamia Berraeis; Zohra Regaya; Faouzi Jenhani
Journal:  World J Stem Cells       Date:  2011-11-26       Impact factor: 5.326

2.  Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.

Authors:  Miao-Chia Lo; Luke F Peterson; Ming Yan; Xiuli Cong; Fulai Jin; Wei-Jong Shia; Shinobu Matsuura; Eun-Young Ahn; Yukiko Komeno; Minh Ly; Hans B Ommen; I-Ming Chen; Peter Hokland; Cheryl L Willman; Bing Ren; Dong-Er Zhang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

3.  Not just a marker: CD34 on human hematopoietic stem/progenitor cells dominates vascular selectin binding along with CD44.

Authors:  Dina B AbuSamra; Fajr A Aleisa; Asma S Al-Amoodi; Heba M Jalal Ahmed; Chee Jia Chin; Ayman F Abuelela; Ptissam Bergam; Rachid Sougrat; Jasmeen S Merzaban
Journal:  Blood Adv       Date:  2017-12-26

4.  Serum after autologous transplantation stimulates proliferation and expansion of human hematopoietic progenitor cells.

Authors:  Thomas Walenda; Gudrun Bokermann; Edgar Jost; Oliver Galm; Anne Schellenberg; Carmen M Koch; Daniela M Piroth; Wolf Drescher; Tim H Brümmendorf; Wolfgang Wagner
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

5.  Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.

Authors:  Richard K Lubberich; Thomas Walenda; Tamme W Goecke; Klaus Strathmann; Susanne Isfort; Tim H Brümmendorf; Steffen Koschmieder; Wolfgang Wagner
Journal:  PLoS One       Date:  2018-05-31       Impact factor: 3.240

Review 6.  Characterization of Endothelial Progenitor Cell: Past, Present, and Future.

Authors:  Amankeldi A Salybekov; Shuzo Kobayashi; Takayuki Asahara
Journal:  Int J Mol Sci       Date:  2022-07-12       Impact factor: 6.208

7.  Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells.

Authors:  Thomas Walenda; Simone Bork; Patrick Horn; Frederik Wein; Rainer Saffrich; Anke Diehlmann; Volker Eckstein; Anthony D Ho; Wolfgang Wagner
Journal:  J Cell Mol Med       Date:  2009-05-11       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.